Based on a recent report demonstrating synergy between arsenic trioxide (ATO) and TRAIL in myeloma cells, we were interested in exploring the potential of ATO as a TRAIL-sensitising agent in leukaemic cells (Liu et al, 2003). Here, TNFSF10 is linked to plasma cell myeloma.